KROS FY 2019 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$424M

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+0.0% YoY

Gross Profit

-$7M-73.5% margin

Operating Income

-$11M-105.6% margin

Net Income

-$12M-123.4% margin

EPS (Diluted)

$-1.39

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$11M

Total Liabilities

$10M

Stockholders' Equity

$495,000

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$10M	+0.0%
Gross Profit	-$7M	-$111,000	-6519.8%
Operating Income	-$11M	-$2M	-524.7%
Net Income	-$12M	-$1M	-824.6%